ArticleLeukemia2023

Evaluation of complete response to azacitidine according to the revised International Working Group 2023 response criteria for higher risk MDS. Does it make a difference in patients' outcome?

Anthi Bouchla et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.